Lucia Wealth Services LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 4.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 191,956 shares of the company’s stock after acquiring an additional 8,858 shares during the period. Johnson & Johnson accounts for approximately 6.7% of Lucia Wealth Services LLC’s holdings, making the stock its largest position. Lucia Wealth Services LLC’s holdings in Johnson & Johnson were worth $28,578,000 at the end of the most recent quarter.
Other hedge funds have also bought and sold shares of the company. Hussman Strategic Advisors Inc. bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth $1,519,000. Heritage Wealth Advisors boosted its holdings in shares of Johnson & Johnson by 2.6% during the 3rd quarter. Heritage Wealth Advisors now owns 75,723 shares of the company’s stock worth $11,274,000 after buying an additional 1,908 shares during the period. Illinois Municipal Retirement Fund boosted its holdings in shares of Johnson & Johnson by 379.7% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 46,929 shares of the company’s stock worth $6,987,000 after buying an additional 37,146 shares during the period. CWH Capital Management Inc. boosted its holdings in shares of Johnson & Johnson by 2.5% during the 3rd quarter. CWH Capital Management Inc. now owns 18,694 shares of the company’s stock worth $2,783,000 after buying an additional 459 shares during the period. Finally, LFA Lugano Financial Advisors SA bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth $228,000. 67.44% of the stock is owned by institutional investors.
Several analysts recently issued reports on the stock. Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Friday. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Credit Suisse Group upped their target price on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research note on Wednesday, October 14th. Stifel Nicolaus cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Finally, Cantor Fitzgerald upped their target price on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Buy” and an average target price of $164.93.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The firm had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. During the same quarter in the prior year, the firm earned $2.12 EPS. The company’s revenue was up 1.7% on a year-over-year basis. On average, equities analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio is currently 46.54%.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.27% of the stock is owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Further Reading: Technical Indicators – What is a Golden Cross?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.